CEL-SCI Successfully Produces and Fills Multikine in New Manufacturing Facility

Published August 4, 2010

CEL-SCI Successfully Produces and Fills Multikine in New Manufacturing Facility
VIENNA, Va.—-CEL-SCI Corporation announced today that it has successfully produced and filled its first lot of Multikine® in preparation for the upcoming pivotal Phase III trial targeting advanced primary head and neck cancer.
Read more on Business Wire via Yahoo! Finance

Dendreon says Provenge sales topped M in July
Dendreon Corp. on Tuesday reported a wider second-quarter loss on higher costs but said sales of its prostate cancer treatment Provenge are rising rapidly and now total more than $ 5 million a month.
Read more on AP via Yahoo! Finance

DNDN’s Loss Up on Higher Costs
Dendreon Corp.’s second quarter 2010 loss of 49 cents per share was wider than the year-ago loss of 20 cents per share.
Read more on Zacks.com via Yahoo! Finance